Parkside Financial Bank & Trust’s Celldex Therapeutics CLDX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9K	Hold	51	–	–	﹤0.01%	2196
2026 Q1	$1.62K	Hold	51	–	–	﹤0.01%	2195
2025 Q4	$1.39K	Hold	51	–	–	﹤0.01%	2227
2025 Q3	$1.32K	Buy	51 +26	+104%	+$602	﹤0.01%	2172
2025 Q2	$510	Sell	25 -15	-38%	-$292	﹤0.01%	2539
2025 Q1	$726	Buy	+40	New	+$894	﹤0.01%	2210

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parkside Financial Bank & Trust's CLDX Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 51 shares worth $1.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Parkside Financial Bank & Trust first reported a position in CLDX in Q1 2025 and has held it in 6 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Parkside Financial Bank & Trust held 51 shares of Celldex Therapeutics worth $1.9K as of Q2 2026.
Parkside Financial Bank & Trust left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2196 holding.
Parkside Financial Bank & Trust first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 6 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.